Evidence map›Paper›PMID 27134651›Full record

ArticleJournal of biological engineering2016

Seamless site-directed mutagenesis of the Saccharomyces cerevisiae genome using CRISPR-Cas9.

Damien Biot-Pelletier, Vincent J J Martin

Open access · goldAbstract read
In one paragraph

Article in Journal of biological engineering, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Strategies for High-Efficiency Mutation Using the CRISPR/Cas System.Frontiers in cell and developmental biology · 2021
    Review
  10. Precise Replacement ofG3 (Bethesda, Md.) · 2020
    Article
  11. Review
  12. Development and Application of CRISPR/Cas in Microbial Biotechnology.Frontiers in bioengineering and biotechnology · 2020
    Review
  13. CRISPR/Cas9 Systems for the Development ofFrontiers in bioengineering and biotechnology · 2020
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Damien Biot-PelletierDepartment of Biology, Concordia University, 7141 Sherbrooke West, Montréal, QC H4B 1R6 Canada ; Centre for Structural and Functional Genomics, Concordia University, 7141 Sherbrooke West, Montréal, QC H4B 1R6 Canada.
Vincent J J MartinDepartment of Biology, Concordia University, 7141 Sherbrooke West, Montréal, QC H4B 1R6 Canada ; Centre for Structural and Functional Genomics, Concordia University, 7141 Sherbrooke West, Montréal, QC H4B 1R6 Canada.
Concordia University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR assisted homology directed repair enables the introduction of virtually any modification to the Saccharomyces cerevisiae genome. Of obvious interest is the marker-free and seamless introduction of point mutations. To fulfill this promise, a strategy that effects single nucleotide changes while preventing repeated recognition and cutting by the gRNA/Cas9 complex is needed. We demonstrate a two-step method to introduce point mutations at 17 positions in the S. cerevisiae genome. We show the general applicability of the method, enabling the seamless introduction of single nucleotide changes at any location, including essential genes and non-coding regions. We also show a quantifiable phenotype for a point mutation introduced in gene GSH1. The ease and wide applicability of this general method, combined with the demonstration of its feasibility will enable genome editing at an unprecedented level of detail in yeast and other organisms.

Indexed as

CRISPR-Cas9Genome editingSaccharomyces cerevisiaeSite-directed mutagenesis

Identifiers

PMID27134651
PMCPMC4850645
OpenAlexW2344328354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.